In Vivo CRISPR Therapeutics
Direct delivery of genome editors into the body to treat disease without removing cells for ex vivo manufacturing.
Core metadata
- ID: in_vivo_crispr_therapeutics
- Era: Future
- First known date: 2030 (decade)
- Region: Forecast / global medicine
- Review status: source_checked
- Maturity: forecast
Prerequisites
- Base Editing (base_editing)
- CRISPR Delivery: AAV, LNP, and RNP (crispr_delivery_aav_lnp_rnp)
- CRISPR Off-Target Profiling (crispr_off_target_profiling)
Dependents
- None.
Fields
Field lanes
- Genome Editing / CRISPR-Cas: Roadmap
Node sources
- Drug delivery systems for CRISPR-based genome editors (Nature Reviews Drug Discovery, 2023, review) • Supports: node, maturity, roadmap
- The 60-year evolution of lipid nanoparticles for nucleic acid delivery (Nature Reviews Drug Discovery, 2024, review) • Supports: node, maturity, roadmap
Prerequisite edge evidence
Edge/source evidence summary:
- Prerequisite edges: 3
- Average edge confidence: 49%
- Prerequisite sources: 3
- expert_inference: 1
- speculative: 2
| Prerequisite | Type | Confidence | Evidence level | Note | Sources |
|---|---|---|---|---|---|
| CRISPR Delivery: AAV, LNP, and RNP (crispr_delivery_aav_lnp_rnp) | commercial_or_scaling_dependency | 78% | expert_inference | In vivo therapy depends heavily on safe tissue-targeted delivery. |
|
| CRISPR Off-Target Profiling (crispr_off_target_profiling) | speculative | 35% | speculative | CRISPR Off-Target Profiling is a plausible dependency for a forecast technology and should be treated as speculative. |
|
| Base Editing (base_editing) | speculative | 35% | speculative | Base Editing is a plausible dependency for a forecast technology and should be treated as speculative. |
|
This page is generated from canonical era JSON and is indexable by URL.